To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...

VANCOUVER, British Columbia, November 07, 2024 -- ( BUSINESS WIRE )-- AbCellera (Nasdaq: ABCL) today announced new data on ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted ...

Liver failure encompasses a range of severe clinical syndromes resulting from the deterioration of liver function, triggered ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...

Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS ... Safety concerns include low levels of grade ...